Strong REZOLVE-AA Study Results Drive Analyst Confidence in Nektar Therapeutics (NKTR)
The trial narrowly missed its primary endpoint; however, Oppenheimer highlighted that omitting four patients with eligibility violations yielded nominal statistical significance.






